Towards Better Delivery of Cannabidiol (CBD)

Pharmaceuticals

SaoirseElizabeth O’Sullivan¹  SophieAnne Millar¹  AndrewStephen Yates¹  RyanFrancis Maguire² 

[1] Artelo Biosciences, 888 Prospect Street, Suite 210, La Jolla, CA 92037, USA;Division of Graduate Entry Medicine and Medical Sciences, School of Medicine, University of Nottingham, Royal Derby Hospital, Derby DE22 3DT, UK;

关键词: cannabidiol;    CBD;    formulation;    clinical development;   

DOI  :  10.3390/ph13090219

来源: DOAJ

【 摘 要 】

Cannabidiol (CBD) has substantial therapeutic potential, but its development as an effective drug by the pharmaceutical industry is hindered by intrinsic characteristics such as low bioavailability, low water solubility, and variable pharmacokinetic profiles. Importantly, lack of patentability of the drug substance also limits the likelihood of an expensive, full development programme in anything other than orphan indications. Potential avenues to overcome these issues with CBD include self-emulsifying drug delivery systems, improved crystal formulations and other solid-state delivery formulations, which are mostly in the pre-clinical or early clinical stages of development. This review identifies issues compromising current delivery of solid-state CBD, and how advanced pharmaceutical development strategies can enable CBD to realise the full potential as a successful therapeutic agent.

【 授权许可】

Unknown